Top news of the week from The American Journal of Pharmacy Benefits.
5. FDA Issues Special Protocol Agreement for Severe Bipolar Depression Treatment
NRX-101 is the first drug regimen designed to treat severe bipolar depression and acute suicidal ideation and behavior. Read more.
4. FDA OKs Therapy for BRAF Mutation-Positive Anaplastic Thyroid Cancer
The FDA approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic. Read more.
3. Experimental Drug Shows Promise in Schizophrenia
Treatment with RBP-7000 significantly reduced Positive and Negative Syndrome Scale (PANSS) total score and greatly increased the percentage of adults with schizophrenia achieving treatment response. Read more.
2. Substance Use Worsens Myocardial Infarction Outcomes
Adults that use marijuana and cocaine generally experience the worst possible outcomes of a myocardial infarction (MI), according to a recent study. Read more.
1. Easy Access to Opioids Among Main Concerns of Americans
More US adults believe that it is easy to get access to opioids for unlawful use, with millennials believing this more so than baby boomers. Read more.